CERTAIN PROTEIN KINASE INHIBITORS Russian patent published in 2018 - IPC C07D487/04 C07D491/04 C07D495/04 A61K31/519 A61K31/53 A61K31/5377 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) and/or a pharmaceutically acceptable salt thereof. In formula (I), X is C; Y is O or S; 6 to 5-member condensed ring system A-B is selected from:

and ,

Q is selected from heteroaryl; R¹ is selected from: hydrogen, C_1-6 alkyl, heterocyclyl, heterocyclyl-C_1-4 alkyl, wherein heterocyclyl is unsubstituted or is substituted with at least one substituent, wherein one, two, three or four substituents are independently selected from R^6a; R² selected from: C_3-10 cycloalkyl, wherein the cycloalkyl is unsubstituted or is substituted with at least one substituent independently selected from R^6a; R³ and R⁴ are independently selected from: hydrogen, C_1-10 alkyl and C_3-10 cycloalkyl; or R³ and R⁴ together with the nitrogen atoms to which they are attached form a 4 to 6 membered ring containing 0 or 1 heteroatom independently selected from oxygen and nitrogen and optionally substituted with 1 R^6a; each R⁵ independently selected from: C_1-10 alkyl, -C(O)R⁷; each R^6a independently selected from: -C_1-10 alkyl, -OR⁸, -NR⁷R⁸, -(CR⁹R¹⁰)_tOR⁸, -(CR⁹R¹⁰)_tS(O)_rR⁸, -C(O)R⁷ and -C(O)NR⁷R⁸; each R⁷ and each R⁸ independently selected from: hydrogen and C_1-10 alkyl, wherein alkyl is unsubstituted or substituted with one substituent R^6a; or R⁷ and R⁸ together with the atom(s) to which they are attached form a heterocyclic ring comprising 6 members, containing 0 or 1 additional heteroatom, independently selected from oxygen and nitrogen, and optionally substituted with 1 R^6a; each R⁹ and each R¹⁰ are independently selected from: hydrogen; m is independently selected from 0 and 1; each r is 2; each t is independently selected from 1, 2 and 3; wherein heteroaryl is 6-membered aromatic monocyclic rings containing from 1 to 2 heteroatoms selected from N, the remaining ring atoms being carbon atoms; 9-10 membered bicyclic rings containing from 2 to 3 heteroatoms selected from N, the remaining ring atoms being carbon atoms, and wherein at least one heteroatom is present in the aromatic ring; wherein the heterocyclyl is one aliphatic ring containing 6 ring atoms containing 1-2 heteroatoms independently selected from oxygen and nitrogen; or a bicyclic ring system containing from 6 to 10 ring atoms containing 1-3 heteroatoms independently selected from oxygen and nitrogen; and wherein the heterocycle can be substituted with oxo. Invention also relates to a pharmaceutical composition, methods for modulating cyclin-dependent kinase 4/6, methods of treatment, improvement or prevention of a condition that responds to the inhibition of cyclin-dependent kinase 4/6, to methods for treating a cell proliferative disorder.

.

EFFECT: technical result: obtaining novel compounds of formula (I) which can inhibit the activity of cyclin-dependent kinase 4/6.

19 cl, 4 tbl